GerhardCarlHildebrandtMDDr. med. habil., FACP
Hematology • Columbia, MOHematologic Oncology
Professor of Medicine
Dr. Hildebrandt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
One Hospital Drive
Columbia, MO 65212Phone+1 573-882-8445Fax+1 573-884-6292
Education & Training
Johannes Gutenberg University of Mainz Faculty of MedicineClass of 1997
Certifications & Licensure
KY State Medical License 2014 - 2025
MO State Medical License 2022 - 2025
LA State Medical License 2009 - 2017
UT State Medical License 2012 - 2015
Clinical Trials
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Publications & Presentations
PubMed
- 33 citationsDonor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation.Gerhard C. Hildebrandt, Krystyna M. Olkiewicz, Sung Choi, Leigh A. Corrion, Shawn G. Clouthier
Blood. 2005-03-15 - 73 citationsBlockade of CXCR3 Receptor:Ligand Interactions Reduces Leukocyte Recruitment to the Lung and the Severity of Experimental Idiopathic Pneumonia SyndromeGerhard C. Hildebrandt, Leigh A. Corrion, Krystyna M. Olkiewicz, Bao Lu, Kathleen P. Lowler
Journal of Immunology. 2004-08-01 - 70 citationsDonor-derived TNF-α regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantationGerhard C. Hildebrandt, Krystyna M. Olkiewicz, Leigh A. Corrion, Yayi Chang, Shawn G. Clouthier
Blood. 2004-07-15
Journal Articles
- Age Adjusted Hematopoietic Stem Cell Transplant Comorbidity Index Predicts Survival in a T-cell Depleted Cohort☆Swati Yalamanchi, Hayder Saeed, Dianna Howard, Gerhard C Hildebrandt, Roger Herzig, Gregory Monohan, ScienceDirect
Abstracts/Posters
- Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial ...Gerhard C. Hildebrandt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Disparities in Plasma Cell Neoplasms in Kentucky, Appalachia and Other States: A Population Based StudyGerhard C. Hildebrandt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Includi...Gerhard C. Hildebrandt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Ellis Fischel Cancer Center Becomes AACI’s Newest MemberDecember 27th, 2022- Siteman to Collaborate with University of Missouri on Cancer Research, with Aim to Improve CareSeptember 20th, 2022
- Researchers Discover Potential Treatments for Common Complication Following Bone Marrow TransplantFebruary 15th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
